Xenetic Biosciences, Inc. (XBIO) Reports $1.7M Q3 Net Loss; Share Exchange Proposed

Xenetic reported Q3 net loss of approximately $1.7M, or $0.72 per share, versus $0.5M, or $0.33, a year earlier. Its proposed share exchange with Santersus is expected to create a Nasdaq-listed clinical-stage company; closing is subject to conditions.Material DetailsContext by AI AnalystThis is an…